When will the WESTCORT patents expire, and when will WESTCORT go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	WESTCORT	hydrocortisone valerate	CREAM;TOPICAL	017950-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sun Pharm Inds Inc	WESTCORT	hydrocortisone valerate	OINTMENT;TOPICAL	018726-001	Aug 8, 1983		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: May 21, 2026

Executive summary: Westcort (hydrocortisone valerate) is an established, low-growth US topical corticosteroid with broad generic availability. The core investment driver is not new exclusivity but business continuity: price erosion, channel mix, contracting dynamics, and at-the-margin differentiation through formulation, pack size, and payer or wholesaler placement. From an IP standpoint, Westcort’s value has largely shifted from brand exclusivity to brand-specific trade and supply relationships, because topical steroid access in the US typically turns on non-patent market barriers (formulary, supply stability, and customer contracts) rather than enforceable remaining monopolies.

What is Westcort (hydrocortisone valerate) used for and what is the US market context?

Featured snippet answer: Westcort is a topical corticosteroid indicated for inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (adult and pediatric populations depending on labeling). It competes in a crowded topical steroid category dominated by multisource generics.

Indication scope and clinical positioning

Westcort’s positioning is consistent with class use: short-course management of steroid-responsive inflammatory skin conditions. In US dermatology, payer preference typically favors low-cost topical corticosteroids and step therapy, with higher-strength or novel delivery systems used when standard products fail.

Formulation and regimen considerations that affect purchasing

Topical corticosteroids compete on:

Potency class and acceptable safety profile (site of use, duration limits)
Vehicle tolerability (ointment/cream/lotion differences)
Patient adherence (grease, residue, application comfort)
Pack size and pharmacy dispensing economics

Westcort’s investment implication is that demand is price sensitive and adherence-driven, not innovation-driven.

Competitive landscape

The topical steroid market is saturated with:

Immediate generic substitution at pharmacy level for strength and vehicle-appropriate products
OTC adjacent activity for milder disease where appropriate
Increased use of combination products in some segments (when clinically justified)

What patents protect Westcort and how strong is the patent estate for exclusivity?

Featured snippet answer: Westcort’s active ingredient is hydrocortisone valerate, a long-established molecule. In practice, branded topical steroids typically have limited remaining enforceable patent life as markets mature and generics enter. The investment case therefore hinges on whether any remaining, specific Orange Book-listed patents cover Westcort as marketed, and whether they are still in force or subject to expiration/earlier expiration for each listed code.

How to evaluate the Westcort patent estate (investment lens)

For a topical prescription product, value protection usually comes from:

Composition-of-matter patents (API and derivatives)
Formulation/vehicle patents (specific concentration and vehicle)
Method-of-use patents (rare for mature topical steroid molecules)
Packaging or manufacturing process patents (less common to sustain brand monopolies)

In a mature commodity like hydrocortisone valerate, composition-of-matter protection is typically expired by now. The remaining risk for generic entry is usually determined by whether any formulation or use patents are still listed and enforceable in the Orange Book.

Orange Book as the gating item

The US FDA Orange Book is the first pass for enforcement and generic challenge mapping: listed patents and exclusivity are what can be leveraged in litigation and Paragraph IV disputes. For Westcort, the investment conclusion depends on whether it has:

Current Orange Book listings tied to the marketed product strength and dosage form
Remaining patent term past the present date
Exclusivity status that bars generic approval through 5-year or 3-year exclusivity mechanisms

Because Westcort is a legacy topical steroid brand, the likely outcome is that enforceable exclusivity has largely run off and generic competition has already rationalized pricing.

When does Westcort lose exclusivity and what are the practical generic entry timelines?

Featured snippet answer: Westcort’s practical exclusivity and pricing power have already diminished in prior cycles because topical hydrocortisone valerate is a mature, multisource active ingredient in the US.

Exclusivity vs patent term vs market reality

Even if a patent were to remain, generic entry timing in topical steroids often follows:

Orange Book listing status
Launch readiness at scale
Contracting and rebate structures that keep prices suppressed
Channel substitution rates after launch

Investment implications

Expect limited brand duration uplift from “patent overhang” unless a specific, in-force formulation patent exists for the exact strength/vehicle.
Treat any ongoing branded revenue as contract- and logistics-driven rather than exclusivity-driven.

How many patents and what type of claims typically cover hydrocortisone valerate topical products?

Featured snippet answer: In mature topical steroid classes, the likely patent mix narrows to formulation and process claims, while core composition-of-matter protection is expired.

Claim-type mapping for investment prioritization

For topical steroid investors, the relevant question is not total patent count but enforceable scope:

Does a remaining patent claim the specific concentration and vehicle?
Are claims narrow to a manufacturing method that generics would avoid?
Do method-of-use claims map to clinically used regimens that a generic label would need to match?

Litigation and “design-around” probability

Formulation patents are often easier to design around than composition-of-matter, and manufacturing/process patents are often circumventable unless they constrain the manufacturing window tightly.

What patent litigation affects Westcort and what generic entry risks exist?

Featured snippet answer: Westcort’s generic entry risk is largely realized and ongoing risks are mostly limited to incremental substitutions rather than brand-blocking litigation, given category maturity.

How to frame litigation risk for a mature topical brand

Even with litigation, the investment-relevant outcomes usually reduce to:

Settlement terms that delay launch
License agreements that allow early or shared revenue under royalty terms
Court rulings that confirm claim validity or obviousness

Generic entry risk categories that matter now

Launch timing risk: already passed for most entrants; remaining entrants can still expand SKUs or switch pack sizes.
Labeling risk: bioequivalence frameworks are less central for topical creams/ointments than oral generics, but labeling and vehicle equivalence matter.
Supply risk: brand share can be influenced by the incumbent’s ability to fulfill and by competitor supply interruptions.

What is the Orange Book status of Westcort (hydrocortisone valerate) and what does it mean for investors?

Featured snippet answer: The Orange Book status determines which patents remain enforceable against FDA-approved generics. For a mature topical corticosteroid like Westcort, investors should assume Orange Book-listed protection has limited practical effect unless current, in-force patents still cover the exact product.

What to extract from Orange Book for an investment model

A robust model pulls:

Patent numbers and expiration dates
Patent types (drug substance, drug product, method-of-use)
Exclusivity codes
NDA/BLA linkages to ANDAs for generics

Investment interpretation

If Orange Book patents are expired or close to expiration, the brand’s revenue future is primarily driven by commercial execution and contract dynamics.
If patents remain and are formulation-specific, it can support selective retention of pricing power.

How does Westcort compare with other topical corticosteroids for competitive differentiation?

Featured snippet answer: Westcort competes as a conventional topical steroid product in a crowded space where differentiation is typically packaging, vehicle preference, and contracting rather than clinical superiority.

Competitive set to consider in an investment view

Investors generally benchmark against:

Generic hydrocortisone valerate equivalents in matching strength and vehicle categories
Mid-potency topical steroids with stronger payer preference under step edits
Combination products and non-steroidal adjuncts in certain dermatitis indications

What matters for brand economics

Pharmacy switching rates by molecule and vehicle
PBM formularies and tier position
Patient out-of-pocket differentials at the point of dispensing
Wholesale channel stocking and rebate frameworks

What manufacturing and IP barriers exist for hydrocortisone valerate topical products?

Featured snippet answer: For mature APIs, the key barriers are operational (GMP scale, formulation consistency, stability, and QC) rather than IP barriers.

Operational levers that influence brand survival

Shelf-life and stability
Consistent particle/dispersion characteristics for creams/ointments
Packaging compatibility (leachables, container closure integrity)
Cost-to-serve across NDCs and pack sizes

Investment angle

The brand incumbent can sometimes sustain share through:

Better supply reliability
Lower backorder rates
Stronger wholesaler positioning
Support for provider education and contracting

Regulatory pathway: how do ANDAs typically enter for topical corticosteroids like Westcort?

Featured snippet answer: Generic topical corticosteroids generally enter via ANDAs with bioequivalence or other demonstration requirements appropriate to topical products, guided by FDA’s pathway rules for generic drugs.

Regulatory milestones that affect market timing

ANDA submission readiness
Facility readiness and approval timelines
Label negotiations
Launch logistics

Implication

Once approvals are cleared, pricing often compresses quickly; the investment case therefore depends on whether brand revenue is protected by contracts, not by regulatory timing.

Commercial fundamentals: what drives revenue and margins for Westcort in 2026?

Featured snippet answer: For Westcort, revenue depends on remaining branded share and channel preference, while margins are pressured by generic price competition and wholesaler/PBM discounts.

Key commercial levers

Net price: brand discounts vs generic benchmark pricing
Volume: stability of prescriptions versus substitution
Mix: pack size and strength distribution
Channel economics: rebates, chargebacks, and wholesaler terms
Contracting: PBM and integrated delivery network formularies

Investment conclusion on fundamentals

Treat Westcort-like brands as “cash management” assets with limited upside from innovation.
Upside tends to come from premium placement agreements, supply strength, or avoidance of stock-outs that preserve share.

Investment scenario analysis: base, downside, and upside cases for Westcort

Featured snippet answer: The base case assumes continuing generic-driven price pressure with modest share retention. Upside requires sustained brand placement or a temporary supply/contract advantage. Downside comes from intensified generic substitution, formulary downgrades, or supply disruptions by the incumbent or key competitors.

Base case (most likely)

Modest volume decline or stable volume with falling net price
Margin compression due to discounting and competitive pricing
Brand share slowly erodes, but remains due to contracting and prescriber inertia

Downside case

Formularies re-tier to generic-only preferences
Additional low-priced entrants expand NDC coverage
Higher discount pressure and increased promotional spend to maintain share

Upside case

Incumbent secures favorable contracting or premium formulary positioning
Competitor supply constraints or quality issues reduce generic availability
Mix improves via pack size or strength demand stability

Key Takeaways

Westcort is a mature topical corticosteroid with investment fundamentals dominated by generic competition and channel contracting, not fresh patent-driven exclusivity.
The Orange Book and any remaining in-force patents determine legal barriers, but category maturity suggests limited incremental exclusivity leverage.
Revenue durability depends on net price, volume retention, and supply reliability more than on IP.
Model Westcort as a cash-flow and channel-execution asset with base case price compression and share erosion, plus scenario-based upside from contracting or competitor supply shocks.

FAQs

Is Westcort still a brand after generic substitution?
Yes, Westcort persists as a marketed brand, but its practical market position is constrained by multisource hydrocortisone valerate generics.
Do topical steroid patents typically block generic launch through Orange Book listings?
They can, but for legacy molecules the remaining enforceability is usually limited to narrow formulation or method claims, if any.
What commercial events most quickly change Westcort pricing?
PBM formulary moves, new generic launches in matching NDCs/pack sizes, and renegotiated wholesaler/PBM rebate terms.
Are method-of-use patents common for hydrocortisone valerate topical products?
For mature topical steroid actives, method-of-use patents are less common as the IP focus shifts to formulation or manufacturing, if any.
What operational factors can preserve Westcort share even without patent protection?
Supply reliability, consistent manufacturing quality, stable shelf life, and favorable contracting that prevents rapid switching.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
FDA. (n.d.). Generic Drug User Fee Amendments and generic approval pathways (ANDAs). US Food and Drug Administration. https://www.fda.gov/drugs/generic-drugs

US Patents:	0
Applicants:	1
NDAs:	2

AI Deep Research

Questions you can ask:

Summary for WESTCORT